Myeloma, Amyloidosis, & Dysprotenemia

David S. Viswanatha, M.D., explains how Mayo Clinic Laboratories' new assay provides rapid, definitive diagnosis of VEXAS, a recently identified syndrome affecting older men. Early diagnosis is key to managing the syndrome, which severely impacts multiple organs and blood.

David Murray, M.D., Ph.D., explains how Mayo Clinic Laboratories' MASSFIX Quantitation assay provides next-generation screening for M-proteins, which are associated with multiple myeloma and other diseases. The assay better quantitates the blood proteins, for improved patient care and simpler test ordering.

In this month's "Hot Topic," David Murray, M.D., Ph.D., reviews the role of urine testing for monoclonal gammopathies and discusses Mayo Clinic’s use of MASSFIX to replace traditional immunofixation testing.

The assay is now recommended for diagnosing and monitoring patients with monoclonal protein disorders and exclusively available through Mayo Clinic Laboratories– Rochester.

The results are part of a comprehensive study of 16,175 cases performed at Mayo Clinic over an 11-year period.

Matt Millen, ex-pro NFL player, who played on four Super Bowl-winning teams underwent a nearly six-year medical journey in search for answers. Finally, he was diagnosed with amyloidosis using a new testing methodology at Mayo Clinic.